CD274 and neoplasm: An example is a phase II trial (ACTRN12617000651381) presented at the San Antonio Breast Cancer Symposium 2022 evaluating in high-risk TNBC, the addition of ipilimumab and nivolumab to neoadjuvant paclitaxel following a suboptimal response to anthracycline-based CHT (< 50% tumor reduction) and resulting in promising objective response rate (ORR) (43.7%) and pCR (18.8%) rates, regardless of PD-L1 status.